Patents by Inventor Donald W. Landry

Donald W. Landry has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200165211
    Abstract: In an aspect, the disclosure provides for compounds (II), compositions, and methods of administering the compounds and compositions to a patient in need thereof. In another aspect, the disclosure relates to compounds and compositions for treating cancer, for example, lymphoid leukemia. The disclosure further provides for compounds which inhibit two phosphoinositide 3-kinase (PI3K) isoforms, y and ?, pharmaceutical compositions comprising said compounds, and methods of using said compounds and pharmaceutical compositions for treatment, amelioration, and/or prevention of non-Hodgkin lymphoma.
    Type: Application
    Filed: July 31, 2018
    Publication date: May 28, 2020
    Applicant: The Trustees of Columbia University in the City of New York
    Inventors: Donald W. LANDRY, Shi-Xian DENG, Xiaoming XU, Thomas DIACOVO
  • Patent number: 10653648
    Abstract: The invention provides pharmaceutical compositions and methods for treating cancer, neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels, and/or accumulations of alpha-synuclein by administering a HAT modulator and a HDAC modulator to a subject.
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: May 19, 2020
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Owen Anthony O'Connor, Jennifer Effie Amengual, Donald W. Landry, Ottavio Arancio, Luigi Scotto, Shixian Deng, Rosa Purgatorio, Jole Fiorito
  • Patent number: 10647726
    Abstract: The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, the treatment of ischemic injury, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic cardiomyopathy, infections of the skin, peripheral vascular disease, stroke, asthma, and the like.
    Type: Grant
    Filed: November 6, 2018
    Date of Patent: May 12, 2020
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Andrew Wasmuth, Donald W. Landry
  • Patent number: 10640457
    Abstract: The invention provides for a method for screening compounds that bind to and modulate a histone acetyltransferase protein. The invention further provides methods for treating neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels, and/or accumulations of alpha-synuclein as well as cancer by administering a HAT-activating compound to a subject.
    Type: Grant
    Filed: June 11, 2012
    Date of Patent: May 5, 2020
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Yan Feng, Mauro Fa, Ottavio Arancio, Shixian Deng, Donald W. Landry, Yitshak Francis
  • Patent number: 10639306
    Abstract: The present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, infections of the skin, peripheral vascular disease, stroke, and the like.
    Type: Grant
    Filed: March 5, 2019
    Date of Patent: May 5, 2020
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Andrew Wasmuth, Donald W. Landry, Shixian Deng, Banavara L. Mylari, Ravichandran Ramasamy, Ann Marie Schmidt
  • Patent number: 10626113
    Abstract: The invention provides for novel benzonaphthyridine derivatives and compositions comprising novel benzonaphthyridine derivatives. In some embodiments, the compounds are phosphodiesterase inhibitors. The invention further provides for methods for inhibition of phosphodiesterase comprising contacting phosphodiesterase with novel benzonaphthyridine derivatives or compositions comprising novel benzonaphthyridine derivatives. The invention further provides for methods for treatment of neurodegenerative diseases, increasing memory or long term potentiation with novel benzonaphthyridine derivatives or compositions comprising novel benzonaphthyridine derivatives. In some embodiments, the phosphodiesterase is PDE5.
    Type: Grant
    Filed: July 17, 2014
    Date of Patent: April 21, 2020
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Donald W. Landry, Shixian Deng, Ottavio Arancio, Jole Fiorito, Andrew Wasmuth
  • Publication number: 20200115325
    Abstract: The invention provides for a method for screening compounds that bind to and modulate a histone acetyltransferase protein. The invention further provides methods for treating neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels, and/or accumulations of alpha-synuclein as well as cancer by administering a HAT-activating compound to a subject.
    Type: Application
    Filed: December 9, 2019
    Publication date: April 16, 2020
    Inventors: Yan FENG, Mauro FA, Ottavio ARANCIO, Shixian DENG, Donald W. LANDRY, Yitshak FRANCIS
  • Publication number: 20200101078
    Abstract: The invention provides compounds and compositions comprising compounds that modulate histone acyl transferase (HAT). The invention further provides methods for treating neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tan protein levels, and/or accumulations of alpha-synuclein as well as cancer by administering a compound that modulates HAT to a subject.
    Type: Application
    Filed: December 2, 2019
    Publication date: April 2, 2020
    Inventors: Ottavio ARANCIO, Shixian DENG, Donald W. LANDRY, Jole FIORITO, Rosa PURGATORIO, Owen Anthony O'CONNOR, Jennifer Effie AMENGUAL
  • Patent number: 10485845
    Abstract: The present invention relates to the discovery of a novel molecular pathway involved in long-term hyperexcitability of sensory neurons, which, in higher animals, is associated with persistent pain. It is based on the discovery that, following injury to an axon of a neuron, an increase in nitric oxide synthase activity results in increased nitric oxide production, which, in turn, activates guanylyl cyclase, thereby increasing levels of cGMP. Increased cGMP results in activation of protein kinase G (“PKG”), which then is retrogradely transported along the axon to the neuron cell body, where it phosphorylates MAPKerk.
    Type: Grant
    Filed: July 30, 2015
    Date of Patent: November 26, 2019
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Richard Ambron, Ying-Ju Sung, Donald W. Landry, Shi-Xian Deng
  • Publication number: 20190300543
    Abstract: The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, the treatment of ischemic injury, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic cardiomyopathy, infections of the skin, peripheral vascular disease, stroke, asthma, and the like.
    Type: Application
    Filed: November 6, 2018
    Publication date: October 3, 2019
    Inventors: Andrew WASMUTH, Donald W. LANDRY
  • Publication number: 20190201400
    Abstract: The present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, infections of the skin, peripheral vascular disease, stroke, and the like.
    Type: Application
    Filed: March 5, 2019
    Publication date: July 4, 2019
    Inventors: Andrew WASMUTH, Donald W. LANDRY, Shi Xian DENG, Banavara L. MYLARI, Ravichandran RAMASAMY, Ann Marie SCHMIDT
  • Publication number: 20190194212
    Abstract: The invention relates to new compounds that reduce c-Myc expression and useful for cancer treatment, particularly hematological cancers such as aggressive B- and T-cell lymphomas. The new compounds may be combined with adjunct c-Myc inhibor agents such as a PI3K inhibitor, CK-1 inhibitor, Akt-inhibitor, proteasome inhibitor and/or mTor inhibitor. The c-Myc reducing agent may be provided as a lead-in treatment to reduce or initiate reduction of c-Myc prior to adminstration of the adjunct cancer therapeutic agent. Treatment with a c-Myc reducing agent modulates the disease state of the c-Myc overexpressing cancer making it less malignant and more susceptible to adjunctive cancer therapies.
    Type: Application
    Filed: May 15, 2017
    Publication date: June 27, 2019
    Inventors: Changchun Deng, Mark Lipstein, Owen O'Connor, Donald W. Landry, Xiaoming Xu, Shi-Xian Deng, Xavier O. Jirau Serrano
  • Publication number: 20190070183
    Abstract: The invention relates to the co-administration of select proteasome and PI3K inhibitors is useful for treating c-Myc-overexpressing cancers, particularly hematological cancers such as aggressive B- and T-cell lymphomas. In exemplified embodiments, coadministration of a dual PI3K/CK-1 inhibitor with a proteasome inhibitor synergistically increases cell death of aggressive B- and T-cell lymphomas as well as multiple myeloma over the individual or additive effect of either or both agents. This synergistic effect is associated with the previously unknown inhibition of the kinase casein kinase 1 epsilon (CK-1?) by a PI3K inhibitor, such as TGR-1202. Accordingly, use of PI3K inhibitors that possess CK-1? inhibition in combination with proteasome inhibitors provides a new therapy regime for treating c-Myc-overexpressing cancers, and particularly hematological cancers.
    Type: Application
    Filed: November 4, 2016
    Publication date: March 7, 2019
    Inventors: Changchun Deng, Shi-Xian Deng, Donald W. Landry, Mark Lipstein, Michael Mangone, Owen O'Connor, Xavier O. Jirau Serrano, Luigi Scotto, Xiaoming Xu
  • Publication number: 20180360842
    Abstract: The invention provides compounds and compositions comprising compounds that modulate histone acyl transferase (HAT). The invention further provides methods for treating neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels, and/or accumulations of alpha-synuclein as well as cancer by administering a compound that modulates HAT to a subject.
    Type: Application
    Filed: January 11, 2018
    Publication date: December 20, 2018
    Inventors: Ottavio ARANCIO, Shi Xian DENG, Donald W. LANDRY, Jole FIORITO, Rosa PURGATORIO, Owen Anthony O'CONNOR, Jennifer Effie AMENGUAL
  • Patent number: 10150779
    Abstract: The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, the treatment of ischemic injury, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic cardiomyopathy, infections of the skin, peripheral vascular disease, stroke, asthma, and the like.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: December 11, 2018
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Andrew Wasmuth, Donald W. Landry
  • Patent number: 10125117
    Abstract: Disclosed herein is an in vitro or in vivo method of activating or reversing inactivation of acetylcholinesterase (AChE) or butyrylcholinesterase (BuchE) using compounds of the present disclosure. Also disclosed is a method of treating a subject exposed to a nerve agent using such compounds. Also disclosed is a method of treating organophosphate poisoning in a subject using such compounds. Also disclosed is a method of modulating neuronal signaling and transmission in a subject using such compounds.
    Type: Grant
    Filed: July 15, 2015
    Date of Patent: November 13, 2018
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Milan Stojanovic, Francine Katz, Donald W. Landry
  • Publication number: 20180305314
    Abstract: The present invention relates to compounds that exhibit vasodilatory and anti-inflammatory effects by inhibiting the activity of soluble epoxide hydrolase (sEH). The present invention is also directed to methods of identifying such compounds, and use of such compounds for the treatment of diseases related to dysfunction of vasodilation, inflammation, and/or endothelial cells. In particular non-limiting embodiments, components of the invention may be used to treat hypertension.
    Type: Application
    Filed: June 26, 2018
    Publication date: October 25, 2018
    Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Donald W. Landry, Yuli Xie, Yidong Liu, Gangli Gong, Shi-Xian Deng, Kirsten Alison Rinderspacher
  • Patent number: 10098975
    Abstract: The present invention relates to the use of compounds that selectively bind to activated protein kinase G 1 alpha for imaging the anatomic basis for chronic pain. Such imaging may also be used to objectively quantify chronic pain.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: October 16, 2018
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Andrei O. Koren, Shi-Xian Deng, Donald W. Landry, Chaitanya Divgi
  • Publication number: 20180271865
    Abstract: The present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, infections of the skin, peripheral vascular disease, stroke, and the like.
    Type: Application
    Filed: May 25, 2018
    Publication date: September 27, 2018
    Inventors: Andrew WASMUTH, Donald W. LANDRY, Shixian DENG, Banavara L. MYLARI, Ravichandran RAMASAMY, Ann Marie SCHMIDT
  • Publication number: 20180244603
    Abstract: The invention provides compounds and compositions comprising compounds that modulate histone acyl transferase (HAT). The invention further provides methods for treating neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels and/or accumulations of alpha-synuclein as well as cancer by administering a compound hat modulates HAT to a subject.
    Type: Application
    Filed: May 1, 2018
    Publication date: August 30, 2018
    Inventors: Yitshak FRANCIS, Mauro FA, Ottavio ARANCIO, Jole FIORITO, Shixian DENG, Donald W. LANDRY, Michal LUZAC, Yan FENG